类风湿关节炎糖皮质激素试验多纳入具代表性的真实世界患者:系统评价与Meta分析
该系统评价与Meta分析比较了56项RCT(7053例)与10项队列研究(14688例)中类风湿关节炎(RA)患者接受全身糖皮质激素(GC)治疗的基线特征。在可比较的12项特征中,10项(83%)的RCT估计值与队列研究无差异;但RCT参与者更年轻(-4.7岁,95%CI -7.2至-2.1,p<0.001),红细胞沉降率更高(11.8 mm/h,95%CI 5.7至17.8,p<0.001)。合并症因报告不足无法评估。
要点
- RA糖皮质激素RCT与队列研究的多数基线特征一致,总体可推广性可接受。
- RCT参与者较真实世界患者年轻4.7岁,老年患者的外推性可能受限。
- 合并症因报告不足无法比较,相关可推广性证据仍缺失。
核心结论
- GC-RCTs在RA中的证据对当前真实世界患者具有可接受的可推广性,尤其与RA生物制剂的研究结果相比。
- 但RCT参与者比真实世界患者年轻,可能限制试验结果对老年患者的推广。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE中的RCT及作为对照的队列研究(CSs),对象为接受全身GC治疗的RA患者。
- 纳入56项RCT(7053例参与者)与10项CSs(14688例参与者),对基线特征行随机效应Meta分析并按研究类型分层比较。
- 进一步按病程进行敏感性分析;系统评价注册号PROSPERO CRD42019134675。
主要发现
- 12项特征报告频率足以进行对比分析,其中10/12(83%)的RCT估计值与CS估计值未见差异。
- RCT参与者较CS参与者年轻4.7岁(95%CI -7.2至-2.1;p<0.001)。
- RCT参与者红细胞沉降率较CS参与者高11.8 mm/h(95%CI 5.7至17.8;p<0.001)。
- 合并症因报告不足无法评估。
关键数值与推荐
- RCT与CS比较的12项基线特征中10项(83%)无差异。
- RCT参与者年龄较CS低4.7岁(95%CI -7.2至-2.1;p<0.001)。
- RCT参与者ESR较CS高11.8 mm/h(95%CI 5.7至17.8;p<0.001)。
临床怎么用
- 解读RA糖皮质激素RCT证据时可认为其对真实世界患者总体具可推广性。
- 将GC试验结果应用于老年RA患者时需谨慎,因RCT参与者更年轻。
- 合并症对GC获益风险比的影响缺乏充分报告数据,临床决策需个体化评估。
局限性
- 合并症因报告不足无法评估,相关可推广性无法判断。
- 仅12项基线特征报告频率足以进行对比分析,可比特征有限。
- RCT参与者较真实世界患者年轻,对老年人群的外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Randomized controlled trials (RCTs) are considered the gold standard in clinical research due to credible causality. Their results, however, may not be generalizable to real-world populations. While glucocorticoids (GCs) remain a mainstay of rheumatoid arthritis (RA) treatment, it is unclear whether the results of GC-RCTs are generalizable to current real-world RA patients. METHODS: MEDLINE was searched for RCTs and, as comparators, cohort studies (CSs) in RA evaluating systemic GCs. Random-effects meta-analyses were performed for descriptive baseline characteristics (including general demographics, comorbidities, and disease activity) that have been shown to be able to modify the benefit-risk-ratio of various RA therapeutics. These meta-analyses were stratified by study type (RCT and CS). Stratified estimates were subsequently compared. Further sensitivity analyses were performed stratifying by disease duration. RESULTS: 56 RCTs (7053 participants) and 10 CSs (14,688 participants) were included. 12 characteristics were reported frequently enough to allow for comparative analysis. In 10/12 characteristics (83%), RCT estimates did not appear to differ from CS estimates. However, RCT participants were younger (-4.7 years [95% CI -7.2 to -2.1]; p < 0.001) and had higher erythrocyte sedimentation rates (11.8 mm/h [5.7 to 17.8]; p < 0.001) than CS participants. Comorbidities could not be assessed due to insufficient reporting. CONCLUSION: Our findings suggest that evidence from GC trials in RA is of acceptable generalizability to current real-world patients - especially compared to findings from biologic agents in RA. However, RCT participants were younger than real-world patients, potentially limiting the generalizability of trial results to elderly patients. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD42019134675).
引用
- Palmowski A, Nielsen SM, Buttgereit T, et al. Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020. PMID: 32222381. doi:10.1016/j.semarthrit.2020.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。